Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey.

OBJECTIVE To assess current use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation at US hospitals that participate in the training of pulmonary fellows. DESIGN Surveys were mailed in September 1990 to the head nurses of medical intensive care units at 265 US hospitals that were listed in an annual guide listing pulmonary fellowship training programs. In the survey, sedating drugs were defined as medications prescribed to treat anxiety, agitation, or sleeplessness. These included opiates, anesthetics, or neuroleptic agents when used for any of these purposes. SURVEY RESPONDENTS: Surveys were received from nurses at 164 hospitals (62% response rate) representing 93 medical schools and 100 pulmonary fellowship training programs. Nearly half of the respondents worked at university hospitals. Most worked as head nurses in medical (70%) or medical-surgical (21%) intensive care units (ICUs). RESULTS Sedating drugs were given to patients undergoing mechanical ventilation at virtually all the ICUs surveyed, and 36% used these drugs routinely (greater than 70% of patients). Opiates and benzodiazepines were employed most commonly; haloperidol lactate was widely used as well. Intermittent intravenous injection was the preferred method of administration; 62% of the ICUs also gave these drugs by continuous intravenous infusion. Neuromuscular blocking agents were also used at nearly all the ICUs surveyed; however, most gave these drugs to fewer than 20% of patients experiencing respiratory failure. Orders for the use of sedating drugs and neuromuscular blocking agents were written exclusively by house staff at 65% of the ICUs surveyed. CONCLUSIONS Sedating drugs and neuromuscular blocking agents are widely used for patients requiring mechanical ventilation in ICUs at US teaching hospitals. There is considerable variation in the choice, frequency, and method of administration. Given the expense (up to $1000 a day) and the potential hazards to patients of prolonged deep sedation and paralysis, more research is warranted to determine optimal use of these drugs during mechanical ventilation.

[1]  W. Edwards,et al.  Management of Pain in the Critically Ill , 1990 .

[2]  D. D. Briggs,et al.  Critical care medicine certification and pulmonary disease trainees. , 1990, The American review of respiratory disease.

[3]  R. Grounds,et al.  Propofol for long‐term sedation in the intensive care unit * A comparison with papaveretum and midazolam , 1990, Anaesthesia.

[4]  R. Veselis.  Intravenous narcotics in the ICU. , 1990, Critical care clinics.

[5]  D. Crippen.  The role of sedation in the ICU patient with pain and agitation. , 1990, Critical care clinics.

[6]  R. Miller,et al.  Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. , 1990, Anesthesiology.

[7]  A. Aitkenhead,et al.  COMPARISON OF PROPOFOL AND MIDAZOLAM FOR SEDATION IN CRITICALLY ILL PATIENTS , 1989, The Lancet.

[8]  S. Peat,et al.  The prolonged use of atracurium in a patient with tetanus , 1988, Anaesthesia.

[9]  J. Hunter,et al.  Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. , 1988, British journal of anaesthesia.

[10]  G. Murray,et al.  Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines. , 1988, Heart & lung : the journal of critical care.

[11]  R. Slater,et al.  Prolonged neuromuscular blockade with vecuronium in renal failure , 1988, Anaesthesia.

[12]  H. Nagashima,et al.  A simple method for monitoring muscular relaxation during continuous infusion of vecuronium , 1988, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[13]  Rob Janknegt,et al.  Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? , 1988, Clinical pharmacology and therapeutics.

[14]  F. Donati,et al.  Muscle Relaxants in Clinical Anesthesia , 1988 .

[15]  R. Demling,et al.  The pharmacotherapy of the behavioral manifestations of the ICU syndrome , 1987 .

[16]  G H Beemer,et al.  Continuous Infusions of Muscle Relaxants — Why and How , 1987, Anaesthesia and intensive care.

[17]  J. Bion,et al.  Sedation in intensive care--a postal survey. , 1987, Intensive care medicine.

[18]  J. Martyn,et al.  Clinical pharmacology and drug therapy in the burned patient. , 1986, Anesthesiology.

[19]  R. Jones,et al.  Atracurium infusions in patients with renal failure on an ITU , 1986, Anaesthesia.

[20]  S. Dogra,et al.  Atracurium infusion in the intensive care unit. , 1986, British journal of anaesthesia.

[21]  P. Lilleaasen,et al.  Neuromuscular blocking effects of atracurium, vecuronium and pancuronium during bolus and infusion administration. , 1985, British journal of anaesthesia.

[22]  J. Shelhamer,et al.  Perceptions of a critically ill patient experiencing therapeutic paralysis in an ICU , 1984, Critical care medicine.

[23]  J. Viby-Mogensen,et al.  Clinical assessment of neuromuscular transmission. , 1982, British journal of anaesthesia.

[24]  C. Miller-Jones,et al.  Sedation for ventilation , 1980, Anaesthesia.

[25]  A. Fishman.  Pulmonary Diseases and Disorders , 1980 .

[26]  S. W. Clarke,et al.  Prolonged coma after tetanus. , 1972, British medical journal.